Noble Capital Markets Initiates Equity Research Coverage on Zomedica
Zomedica Corp. (NYSE American:ZOM), a veterinary health company specializing in point-of-care diagnostics and therapeutic products for equine and companion animals, has announced the initiation of company-sponsored equity research coverage by Noble Capital Markets. The research coverage will be conducted by Analyst Robert LeBoyer, with the full report and market data available on Channelchek.
Zomedica Corp. (NYSE American:ZOM), un'azienda sanitaria veterinaria specializzata in diagnostica e prodotti terapeutici per animali equini e da compagnia, ha annunciato l'avvio della copertura di ricerca azionaria sponsorizzata dall'azienda da parte di Noble Capital Markets. La ricerca sarà condotta dall'analista Robert LeBoyer, con il rapporto completo e i dati di mercato disponibili su Channelchek.
Zomedica Corp. (NYSE American:ZOM), una empresa de salud veterinaria especializada en diagnósticos y productos terapéuticos para animales equinos y de compañía, ha anunciado el inicio de la cobertura de investigación de acciones patrocinada por la empresa por parte de Noble Capital Markets. La investigación será realizada por el analista Robert LeBoyer, y el informe completo y los datos de mercado estarán disponibles en Channelchek.
Zomedica Corp. (NYSE American:ZOM)는 말과 반려 동물을 위한 진단 및 치료 제품을 전문으로 하는 수의학 건강 회사로, Noble Capital Markets에 의해 회사 후원 주식 연구 보도의 시작을 발표했습니다. 연구 보고서는 분석가 로버트 르보이어가 진행하며, 전체 보고서와 시장 데이터는 Channelchek에서 확인할 수 있습니다.
Zomedica Corp. (NYSE American:ZOM), une entreprise de santé vétérinaire spécialisée dans les diagnostics et les produits thérapeutiques pour les animaux équins et de compagnie, a annoncé le lancement de la couverture de recherche sur les actions parrainée par l'entreprise par Noble Capital Markets. La recherche sera réalisée par l'analyste Robert LeBoyer, avec le rapport complet et les données de marché disponibles sur Channelchek.
Zomedica Corp. (NYSE American:ZOM), ein Unternehmen im Bereich der Veterinärmedizin, das sich auf Diagnosetechnologien und therapeutische Produkte für Pferde und Haustiere spezialisiert hat, hat den Beginn der von der Firma unterstützten Equity-Recherche durch Noble Capital Markets bekannt gegeben. Die Forschungsabdeckung wird von Analyst Robert LeBoyer durchgeführt, und der vollständige Bericht sowie Marktdaten sind auf Channelchek verfügbar.
- Secured new equity research coverage, potentially increasing market visibility
- Company-sponsored research coverage may indicate independent analyst interest
ANN ARBOR, MI / ACCESSWIRE / November 12, 2024 / Zomedica Corp. (NYSE American:ZOM), a veterinary health company offering point-of-care diagnostics and therapeutic products for equine and companion animals, is pleased to announce that Noble Capital Markets has initiated company-sponsored equity research coverage on the Company. The full report by Noble Capital Markets Research Analyst Robert LeBoyer, as well as news and advanced market data on Zomedica Corp., is available on Channelchek.
About Zomedica
Zomedica is a leading equine and companion animal healthcare company dedicated to improving animal health by providing veterinarians innovative therapeutic and diagnostic solutions. Our gold standard PulseVet ® shock wave system, which accelerates healing in musculoskeletal conditions, has transformed veterinary therapeutics. Our suite of products also includes the Assisi ® Loop line of therapeutic devices and the TRUFORMA ® diagnostic platform, the TRUVIEW ® digital cytology system, and the VetGuardian ® no-touch monitoring system, all designed to empower veterinarians to provide top-tier care. In the aggregate, their total addressable market in the U.S. exceeds
Follow Zomedica
Email Alerts: http://investors.zomedica.com
Facebook: https://m.facebook.com/zomedica
X (formerly Twitter): https://twitter.com/zomedica
Instagram: https://www.instagram.com/zomedica_inc
About Noble Capital Markets
Noble Capital Markets, Inc. was incorporated in 1984 as a full-service SEC / FINRA registered broker-dealer, dedicated exclusively to serving underfollowed small / microcap companies through investment banking, wealth management, trading & execution, and equity research activities. Over the past 37 years, Noble has raised billions of dollars for these companies and published more than 45,000 equity research reports. www.noblecapitalmarkets.com email: contact@noblecapitalmarkets.com
About Channelchek
Channelchek (.com) is a comprehensive investor-centric portal - featuring more than 6,000 emerging growth companies - that provides advanced market data, independent research, balanced news, video webcasts, exclusive c-suite interviews, and access to virtual road shows. The site is available to the public at every level without cost or obligation. Research on Channelchek is provided by Noble Capital Markets, Inc., an SEC / FINRA registered broker-dealer since 1984. www.channelchek.com email: contact@channelchek.com
Investor Relations Contact:
Zomedica Investor Relations
investors@zomedica.com
1-734-369-2555
SOURCE: Zomedica Corp.
View the original press release on accesswire.com
FAQ
What is the significance of Noble Capital Markets initiating coverage on Zomedica (ZOM)?
Who is conducting the research coverage for Zomedica (ZOM) at Noble Capital Markets?
Where can investors access Noble Capital Markets' research report on Zomedica (ZOM)?
